NYSEAMERICAN:TRXCTransEnterix Stock Price, Forecast & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransEnterix in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for TransEnterix.

TransEnterix is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for TransEnterix.

TransEnterix, Inc. (NYSEAMERICAN:TRXC) posted its quarterly earnings results on Thursday, May, 14th. The medical instruments supplier reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.53) by $0.12. The medical instruments supplier had revenue of $0.60 million for the quarter, compared to analyst estimates of $0.54 million. View TransEnterix's earnings history.

1 brokerages have issued 12 month price targets for TransEnterix's stock. Their forecasts range from $1.00 to $1.00. On average, they expect TransEnterix's share price to reach $1.00 in the next twelve months. This suggests a possible upside of 136.7% from the stock's current price. View analysts' price targets for TransEnterix.

Press coverage about TRXC stock has been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. TransEnterix earned a news impact score of -1.9 on InfoTrie's scale. They also gave press coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutTransEnterix.

TransEnterix saw a drop in short interest during the month of April. As of April 30th, there was short interest totaling 3,150,000 shares, a drop of 6.3% from the April 15th total of 3,360,000 shares. Based on an average daily trading volume, of 1,750,000 shares, the short-interest ratio is presently 1.8 days. Approximately 9.8% of the shares of the stock are short sold. View TransEnterix's Current Options Chain.

Some companies that are related to TransEnterix include Omega Diagnostics Group (ODX), Daxor (DXR), Daxor (DXR), IsoRay (ISR), IsoRay (ISR), TSO3 (TOS), Impression Healthcare (IHL), G Medical (GMV), Akers Biosciences (AKR), Relevium Technologies (RLV), Vigil Health Solutions (VGL), Ambu A/S (AMBBY), Ansell (ANSLF), ANSELL LTD/S (ANSLY) and Commerzbank (CZMWY). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other TransEnterix investors own include Oramed Pharmaceuticals (ORMP), Compugen (CGEN), Editas Medicine (EDIT), Ekso Bionics (EKSO), XOMA (XOMA), Actinium Pharmaceuticals (ATNM), Geron (GERN), NVIDIA (NVDA), Advanced Micro Devices (AMD) and Opko Health (OPK).

TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."

TransEnterix's stock is owned by many different retail and institutional investors. Top institutional shareholders include Sabby Management LLC (3.72%), BlackRock Inc. (2.51%), First Trust Advisors LP (1.31%), Russell Investments Group Ltd. (0.89%), State Street Corp (0.60%) and Perkins Capital Management Inc. (0.49%). Company insiders that own TransEnterix stock include Andrea Biffi, Anthony C J Fernando, Joseph P Slattery, Todd Pope, William N Starling Jr and William N Starling, Jr. View institutional ownership trends for TransEnterix.

TRXC stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, and Morgan Stanley. View insider buying and selling activity for TransEnterix.

TRXC stock was purchased by a variety of institutional investors in the last quarter, including Sabby Management LLC, Russell Investments Group Ltd., State Street Corp, Perkins Capital Management Inc., BlackRock Inc., Invesco Ltd., Two Sigma Investments LP, and First Trust Advisors LP. View insider buying and selling activity for TransEnterix.

Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TRXC stock can currently be purchased for approximately $0.42.

TransEnterix has a market capitalization of $21.90 million.

The official website for TransEnterix is www.transenterix.com.

TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400.